Picture this: Pancreatic cancer, that relentless killer claiming lives with a five-year survival rate stubbornly stuck below 20%, is finally showing signs of surrender in 2025. As Anna Berkenblit, the Chief Scientific and Medical Officer at the Pancreatic Cancer Action Network (PanCAN), reflects in her LinkedIn post, the year was packed with forward momentum in research, clinical advancements, and patient support. But here's where it gets controversial—could we be on the verge of transforming this once-'undruggable' disease into something treatable for the masses? Let's dive in and explore how partnerships, innovations, and unwavering purpose are rewriting the story of pancreatic cancer. And this is the part most people miss: despite the hurdles, the community's response is proving that collective action can turn challenges into triumphs.
Anna highlights that while pancreatic cancer remains one of the toughest cancers to combat, 2025 built on real gains in early detection, tailored treatments, team-based care, and data-fueled discoveries. These achievements shine a light on the incredible potential when scientists, doctors, collaborators, and patients unite with a sense of urgency and shared goals. Reflecting on the year, we encountered some tough roadblocks, like instability in government research funding, but there's plenty to cheer about amid the progress.
Historically, bipartisan backing for federal investments in scientific studies has been a bedrock principle in Washington. Yet, this year's suggested budget cuts, freezes, and even a government shutdown threatened to derail advancements, raising alarms about derailing an entire generation of researchers. In a powerful comeback, our community rallied, amplifying voices that couldn't be dismissed, and Congress responded by bolstering bipartisan commitment to cancer research in their spending bills. Now, the key is ensuring these bills get passed to keep lifesaving investigations flowing uninterrupted.
Against this backdrop, 2025 introduced PanCAN's Research Recovery Grants, a lifeline for high-potential studies jeopardized by funding delays. These 'bridge' funds, as they're called, shield promising work from interruptions, maintaining the scientific drive when grant stability is shaky across institutions. By nurturing projects with the greatest promise, these grants protect the strides we've made and pave the way for even bolder breakthroughs in 2026. They also solidify PanCAN's essential role as a major backer of pancreatic cancer research.
As Howard Crawford, PhD, from Henry Ford Health System and a member of PanCAN's Scientific and Medical Advisory Board, puts it: 'PanCAN’s unwavering commitment to identifying new resources for research and advocacy will ensure that progress continues uninterrupted. This is exactly why their comprehensive approach to fighting the world’s toughest cancer is so vital.'
Now, shifting gears to the science itself—2025 was a game-changer for tackling RAS mutations, which fuel over 90% of pancreatic cancers. After years of being seen as impossible to drug, RAS is now within reach, thanks to a broad-acting inhibitor. The standout trial, RASOLUTE 302, just wrapped up enrollment and is testing Revolution Medicines' daraxonrasib (RMC-6236) against chemotherapy in patients with advanced disease. Expect results in 2026. Unlike older RAS drugs that only hit a rare mutation in a tiny group of patients, this multi-selective option could revolutionize care for many more. To clarify for newcomers, RAS is a protein that, when mutated, drives cancer cells to grow uncontrollably—think of it as a faulty engine in the cell's machinery.
The FDA's Priority Review Voucher for daraxonrasib underscores the desperate need for fresh treatments. This could mark the dawn of multiple RAS-targeted therapies, with labs and clinics exploring ways to overcome resistance to single-agent inhibitors, potentially boosting survival rates and quality of life. Imagine a patient whose cancer once seemed unbeatable now having a targeted tool in their arsenal— that's the hope here.
Personalized research powered by data also surged ahead. PanCAN's SPARK platform, a health data hub, is revolutionizing how experts access and interpret patient info, speeding up insights through collaboration. By blending clinical details, genetic data, pathology reports, imaging, and even patients' own accounts, SPARK reveals patterns in how the disease evolves and responds to treatments.
A thrilling leap came from PanCAN's tie-up with Acurion, Inc., using their AI-driven OncoGaze tool on SPARK's digital pathology images. Advanced algorithms spot tumor clues, like homologous recombination deficiency (HRD)—a sign that certain DNA repairs are faulty in cancer cells. Identifying these via images could simplify and cheapen therapy choices, giving patients better starting options without invasive tests. For example, HRD might mean a tumor responds well to specific drugs, avoiding trial-and-error approaches.
Sudheer Doss, PhD, PanCAN’s Chief Business Officer, captures it perfectly: 'The fusion of SPARK’s real-world data with emerging AI technologies represents a unique opportunity to accelerate innovation in pancreatic cancer care. We are uncovering insights with the goals of more precise diagnoses, better treatment decisions, and ultimately, a future in which all patients with pancreatic cancer will thrive.'
Early detection, often called the holy grail for survival, saw major strides too. PanCAN's Early Detection Initiative (EDI) digs into how blood sugar shifts might signal pancreatic cancer risks or aid diagnosis. It also checks if scans for newly diabetic patients catch cancer sooner. Hitting a key milestone, EDI enrolled over 8,800 participants, setting up long-term tracking and analysis. We'll see one-year follow-up data in 2026—exciting stuff for potentially spotting trouble early.
On the treatment front, the FDA greenlit CABOMETYX (cabozantinib), a kinase inhibitor, for pancreatic neuroendocrine tumors (PNETs)—a less common pancreatic cancer type—after other therapies fail. This expands choices for all pancreatic cancer patients, offering hope for better management.
The American Society of Clinical Oncology (ASCO) 2025 meeting buzzed with pancreatic highlights. A phase 3 trial of Novocure's Tumor Treating Fields (TTFields) combined with chemo (gemcitabine plus nab-paclitaxel) slightly boosted survival and reduced pain in advanced cases unsuited for surgery. TTFields, already approved for brain and lung cancers, uses electric fields to disrupt cancer growth and could become a go-to add-on, with studies refining its role.
Other presentations covered biomarker-guided treatments and inequalities in access to detection, care, and trials, emphasizing the disease's complexity and ongoing efforts to fix disparities—think how socioeconomic factors can limit who gets cutting-edge options.
PanCAN's Scientific Summit 2025 gathered top minds for intense brainstorming, spotlighting immunotherapy insights, metastasis mechanisms, tumor environment innovations, and next-gen detection tools. It fostered fresh ideas and highlighted the rise of young researchers, stressing mentorship for tomorrow's leaders. This event proves collaboration is the secret sauce for faster progress.
Patient support got a boost with PanCAN's new alliance with Smart Patients, creating an online hub for real-time connection, sharing, and learning among patients and caregivers. It's all about empowerment during the tough journey.
Despite funding woes, PanCAN rolled out fresh research grants for areas like early detection, tumor studies, equity, and new drugs, fueling paradigm-shifting work. Monthly updates underscored themes like data integration's power, disparity research's importance, young talent's contributions, and cross-sector teamwork—painting a vibrant, adaptive research scene.
Looking forward, pancreatic cancer ranks as the third top cancer killer in the U.S., but 2025's AI diagnostics, precision therapies, detection pushes, trial novelties, patient aids, and funding efforts signal a year of drive and direction. Every breakthrough, alliance, and venture edges us toward routine early finds, stronger, gentler treatments, and brighter futures.
PanCAN stays dedicated to lobbying for boosted federal funds to safeguard scientists' work. As 2025 wraps, the takeaway is clear: pancreatic research is picking up speed to convert discoveries into survivals. From fortifying science foundations to enriching patient tools and sparking bold partnerships, the field charges ahead with resolve and optimism.
PanCAN persists in driving advances for current and future patients, rallying the community to shatter barriers toward a reality where survival is standard, not rare. Early detection becomes routine, therapies prove more potent and tolerable, and every pancreatic cancer patient flourishes.
A huge thank you to PanCAN's amazing backers—donors, volunteers, advocates, and more—whose steadfast dedication fuels our cause and sustains the momentum.
But here's where it gets really thought-provoking: With these rapid advances, are we risking overhyping progress and setting unrealistic expectations for patients? Or is this the tipping point where pancreatic cancer finally gets the attention it deserves? Share your thoughts in the comments—do you agree that bipartisan funding is the key, or should we push for even more private-sector involvement? What controversial aspects of AI in diagnostics worry you most? Let's discuss!
